Vaccine combo aims to supercharge immune attack on HPV-Positive throat cancer
NCT ID NCT05799144
First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study tests whether adding two experimental HPV vaccines (pBI-11 and TA-HPV) to the standard immunotherapy drug pembrolizumab can shrink tumors or slow cancer growth in people with advanced oropharyngeal cancer that is HPV-positive. About 54 adults whose cancer has returned or spread will receive the vaccines and pembrolizumab. The goal is to see if the combination triggers a stronger immune response against the cancer than pembrolizumab alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC OROPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama Birmingham
RECRUITINGBirmingham, Alabama, 35249, United States
-
Vanderbilt University/Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.